Feed ENVB
EN

Enveric Biosciences, Inc.

ENVB · NASDAQ

$1.46 +0.69% (+$0.01)
1M -5.81%
Market Cap $871.6K
P/E Ratio -
Div. Yield -
ROE 168.05%

Bulios Fair Price

$1.72

17.8% upside

Current Price

$1.46

Undervalued Fair Value Overvalued

According to Bulios Fair Price, ENVB is currently undervalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
2/9
Valuation
100 /100
Cheap
P/B 0.11x
EV/FFO N/A
P/E N/A
Growth
0 /100
Declining
Book val. growth 34.21%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A
Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor
ROA 97.60%
ROIC 107.99%
Asset turnover 0.00x
Debt
69 /100
Low
Int. coverage -10,329.20x
Debt/Equity 0.00x
Current ratio 10.21x
Stability
27 /100
Unstable
Profitable years 0
Beta 1.11x
EPS volatility 115.68%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about ENVB
Online

About the company

Enveric Biosciences Inc. (ENVB) is a biopharmaceutical company focused on developing innovative therapeutic products for the treatment of symptoms associated with cancer and other chronic diseases. The company specializes in the research and development of cannabinoid-based therapies and other natural compounds that offer patients hope for relief from pain, inflammation, and other challenges associated with illness.

Sector

Healthcare

Industry

Biotechnology

CEO

Joseph Edward Tucker

Employees

6

Headquarters

Cambridge

Upcoming events

12 NOV

Earnings

Upcoming earnings report

62d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.